Bayer’s new business unit teams up with Mahana Therapeutics to commercialize digital treatments

Bay­er is team­ing up with Ma­hana Ther­a­peu­tics in a “mul­ti-mil­lion-dol­lar” dis­tri­b­u­tion and mar­ket­ing part­ner­ship to com­mer­cial­ize dig­i­tal ther­a­peu­tics, Ma­hana an­nounced to­day.

De­tails in the state­ment from Ma­hana are sparse, and both com­pa­nies de­clined to re­veal more de­tails about the dol­lar amount of the part­ner­ship.

Ma­hana CEO Si­mon Levy said in a state­ment the deal is “among the first ma­jor in­vest­ments ever made by a glob­al life sci­ences com­pa­ny in­to the emerg­ing mar­ket­place for dig­i­tal ther­a­peu­tics” and that the part­ner­ship is with Bay­er’s con­sumer health di­vi­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.